Qualigen Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $6.4 million for the nine months ended September 30, 2025, compared to a loss of $5.4 million for the same period in 2024. This resulted in a loss per share of $4.35, a decrease from $24.93 in the previous year, reflecting a substantial increase in the weighted average number of shares outstanding due to recent equity financing activities. Total expenses for the nine-month period rose to $5.8 million, up from $4.4 million in the prior year, primarily driven by increased general and administrative costs.
The company’s cash position improved significantly, with cash and cash equivalents totaling approximately $38.8 million as of September 30, 2025, compared to $1.2 million at the end of 2024. This increase was largely due to a successful subscription agreement with investors, including Faraday Future, which raised $41 million in September 2025. The funds are earmarked for operational expenses, debt repayment, and the establishment of a cryptocurrency treasury operation. However, the company also reported an accumulated deficit of $129.4 million, raising concerns about its long-term financial viability.
Qualigen's operational focus remains on its lead therapeutic program, QN-302, which is in early clinical development for cancer treatment. The company has also entered into a co-development agreement with Marizyme, Inc., which includes a funding payment structure tied to the commercialization of Marizyme's DuraGraft product. Despite these initiatives, the company has slowed its research and development activities due to financial constraints, leading to a significant reduction in R&D expenses from $1.2 million in 2024 to $0.2 million in 2025.
In terms of organizational changes, Qualigen has seen a restructuring of its leadership team, although the legacy CEO continues to oversee operations. The company has also engaged external consultants to assist with its financial and operational strategies. Despite these efforts, the company faces challenges related to liquidity and ongoing operational losses, which may hinder its ability to continue as a going concern without additional funding or successful commercialization of its products. The management has indicated that it will continue to explore strategic partnerships and capital market opportunities to support its operations moving forward.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics is an early-stage biotech company developing cancer treatments, focusing on small molecule therapeutics targeting genetic structures like G-quadruplexes and RAS oncogenes. Its pipeline includes QN-302 for pancreatic cancer and Pan-RAS inhibitors for multiple cancers. The company collaborates with academic institutions, advances clinical trials, and seeks regulatory approval, aiming to address unmet medical needs in oncology markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.